Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 3/20 | 0.49 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31318817 | 1.00 | TAAR1 (0.57) | TAAR1DRD2DRD1ACHENOS1 | |
| SCHEMBL31662833 | 0.83 | ALDH1A1 (0.48) | NOS1SMN1; SMN2LOXL2ALDH1A1TSHR | |
| SCHEMBL348900 | 0.83 | ALDH1A1 (0.48) | NOS1SMN1; SMN2LOXL2ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL25180658 | 0.82 | ALDH1A1 (0.47) | NOS1SMN1; SMN2LOXL2ALDH1A1TSHR | |
| SCHEMBL169805 | 0.82 | ALDH1A1 (0.47) | TAAR1DRD2DRD1NOS1ALDH1A1 | |
| SCHEMBL6011706 | 0.80 | ALDH1A1 (0.45) | TAAR1NOS1HTR7ALDH1A1TSHR | |
| SCHEMBL6750529 | 0.80 | CALM1 (0.53) | NOS1SMN1; SMN2ALDH1A1TSHRCNR1 | |
| SCHEMBL834162 | 0.80 | ALDH1A1 (0.50) | TAAR1NOS1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL6011704 | 0.80 | ALDH1A1 (0.45) | TAAR1DRD2DRD1NOS1SMN1; SMN2 | |
| SCHEMBL5536959 | 0.80 | ALDH1A1 (0.45) | TAAR1NOS1SMN1; SMN2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332695-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2022-10-20 | — | — | US | disclosed |
| EP-3990112-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RTI International (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114269719-A | Urea derivatives as CB1 allosteric modulators | RTI国际 | 2022-04-01 | — | — | CN | disclosed |
| WO-2020264176-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RTI INTERNATIONAL (US) | 2020-12-30 | — | — | WO | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| WO-2004060880-A1 | AMINOALKYL THIAZOLE DERIVATIVES AS KCNQ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-22 | — | — | WO | disclosed |
| EP-0355098-A1 | NOVEL SULFONAMIDES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE NEW SULFONAMIDES | HUHTAMÄKI OY (FI) | 1990-02-28 | — | — | EP | disclosed |
| WO-1988007991-A1 | NOVEL SULFONAMIDES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE NEW SULFONAMIDES | Huhtamäki Oy (FI) | 1988-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | TAAR1 998/4885DRD2 631/4885DRD1 638/4885 |
| US-20220332695-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | CNR1, CNR2, GPR119 | TAAR1 28/4885DRD2 552/4885DRD1 572/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | TAAR1 1212/4885DRD2 730/4885DRD1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.